IN THE CLAIMS

1-40. (Previously Cancelled)

41. (Presently Amended) A method of reducing depletion of non-autologous hematopoietic cells in a mammal that ~~which substantially~~ lacks ~~functional~~ endogenous B- and T-cells capable of depleting said non-autologous hematopoietic cells, comprising administering to the mammal an effective amount of dichloromethylene diphosphonate such that the number of endogenous macrophages are decreased to a level effective to reduce depletion of transplanted non-autologous hematopoietic stem cells.

42. (Original) The method according to claim 41, wherein the non-autologous hematopoietic cells are injected into the mammal.

43. (Original) The method according to claim 41, wherein the non-autologous hematopoietic cells are made by hematopoietic tissue engrafted into the mammal.

44. (Previously Amended) The method according to claim 41, wherein the mammal is infected with an immunodeficiency virus.

45. (Original) The method according to claim 44, wherein the mammal is human and the virus is human immunodeficiency virus.

46. (Previously Amended) The method according to claim 41, wherein the mammal lacks said endogenous B- and T-cells due to radiation therapy.

47. (Previously Amended) The method according to claim 41, wherein the mammal lacks said endogenous B- and T-cells due to chemotherapy.

48. (Original) The method according to claim 41, wherein the mammal is selected from the group consisting of a human, a mouse, a SCID/SCID mouse, a SCID-hu mouse, and a CID horse.

49. (Original) The method according to claim 48, wherein the mammal is a SCID-hu Thy/Liv mouse.

50. (Original) The method according to claim 41, wherein the mammal is transplanted with non-autologous hematopoietic tissue.

51. (Original) The method according to claim 42, wherein the mammal is human.

52. (Presently Amended) A non-human mammal which:
a) lacks ~~functional~~ endogenous B- and T-cells capable of depleting non-autologous hematopoietic cells;
b) comprises ~~comprising~~ human hematopoietic cells, and
c) ~~wherein the non-human mammal~~ contains a decreased level of endogenous macrophages sufficient to reduce depletion of ~~non-autologous~~ said human hematopoietic cells,
wherein the decreased level of endogenous macrophages is achieved by administering to the mammal an effective amount of dichloromethylene diphosphonate.

53. (Original) The non-human mammal according to claim 52, wherein the mammal contains engrafted human hematopoietic tissue.

54. (Original) The non-human mammal according to claim 53, wherein the non-autologous hematopoietic cells are produced by the engrafted tissue.

55. (Original) The non-human mammal according to claim 52, wherein the mammal is selected from the group consisting of a SCID/SCID mouse, a SCID-hu Thy/Liv mouse, and a CID horse.

56. (Presently Amended) A method of improving or restoring engraftment efficiency ~~efficiency~~ for transplantation of a population of non-autologous hematopoietic cells in a host mammal that ~~which substantially~~ lacks ~~functional~~ endogenous B- and T-cells capable of depleting said non-autologous hematopoietic cells, comprising transplanting non-autologous hematopoietic cells into ~~a~~ said mammal ~~substantially lacking functional endogenous B- and T-cells~~ in conjunction with administering to the mammal an ~~effective~~ amount of dichloromethylene diphosphonate effective to ~~which~~ selectively ~~decreases~~ decrease the number of endogenous macrophages in the host mammal.

57. (Original) The method according to claim 56, wherein the mammal is a human infected with human immunodeficiency virus.

58. (Original) The method according to claim 56, wherein the mammal is selected from the group consisting of a

SCID/SCID mouse, a SCID-hu Thy/Liv mouse, and a CID horse.

59. (Original) The method according to claim 56, wherein the dichloromethylene diphosphonate is liposome-encapsulated.